Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Chronic low-grade inflammation that builds with age, known as inflammaging, floods the bloodstream with cytokines such as TNF-alpha, IL-6, and IL-1beta that tip bone remodeling toward breakdown by driving RANKL signaling, activating osteoclasts, and suppressing the osteoblasts that rebuild bone. This shift accelerates loss of bone mineral density and raises fracture risk, and it is often worsened by visceral fat, gut permeability, senescent cells, low vitamin D, poor sleep, and inactivity. Several factors influence how quickly this process moves in any one person, and the mechanisms, risk markers, and prevention strategies are explained in full detail below.
Because bone wasting is silent until a fracture happens, vague signals like fatigue, joint aches, stiffness, or unexplained pain deserve attention rather than dismissal as normal aging. Take a free, instant, online symptom check to see what your symptoms may point to and to get clear guidance on the next steps worth discussing with a clinician.
Last reviewed for medical accuracy: 08/18/2026
As we age, our bodies often show low-grade, chronic inflammation—a phenomenon known as “inflammaging.” While this silent inflammation doesn’t always cause obvious symptoms, it can quietly undermine bone health, leading to increased fragility and fracture risk. In this article, we’ll explore how systemic cytokines drive bone resorption, the role of CRP levels as an inflammatory marker, and practical steps to slow the process.
• Inflammaging describes the persistent, low-level inflammation associated with aging.
• Unlike the short-term inflammation you’d get from a sprained ankle or an infection, this state lacks the intense redness or pain of acute inflammation.
• It’s driven by continuous activation of the immune system, often fueled by factors like oxidative stress, cellular debris, and changes in gut bacteria.
Over time, inflammaging shifts the balance of bone remodeling. Normally, bone tissue is in constant turnover: old bone is broken down by osteoclasts, and new bone is built by osteoblasts. Chronic inflammation tips the scale toward breakdown, causing net bone loss.
Cytokines are signaling proteins released by immune cells. In inflammaging, certain cytokines remain elevated, including:
Together, these cytokines accelerate the breakdown of bone by boosting osteoclast activity and hampering the bone-building efforts of osteoblasts.
CRP is a protein made by your liver in response to inflammation. Measured in a simple blood test, it’s a widely used marker for:
Elevated CRP levels often correlate with higher rates of bone resorption. While CRP itself isn’t the direct cause of bone loss, it reflects the inflammatory milieu that drives cytokine-mediated bone breakdown.
RANK/RANKL/OPG Pathway Dysregulation
Enhanced Osteoclast Activity
Suppressed Osteoblast Function
Oxidative Stress and Cell Senescence
Inflammaging affects everyone to some degree, but certain factors accelerate the process:
• Age over 60
• Sedentary lifestyle
• Poor diet (high in processed foods, low in anti-inflammatory nutrients)
• Smoking and excessive alcohol
• Chronic diseases (e.g., rheumatoid arthritis, inflammatory bowel disease)
• Obesity (adipose tissue produces inflammatory cytokines)
Regular monitoring of bone density (via DXA scans) and CRP levels can help identify those at higher risk of accelerated bone loss.
Lifestyle Modifications
Supplements and Nutrients
Medical Interventions
Regular Monitoring
If you experience unexplained bone pain, recurrent fractures, or symptoms of an inflammatory condition (like persistent joint swelling), it’s important to get professional guidance. You might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help clarify your concerns and decide on next steps.
Always speak to a doctor about anything that could be life threatening or seriously affecting your health.
By understanding the mechanisms of inflammaging and taking proactive steps, you can protect your bones and maintain strength well into later life.
(References)
* Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003 May 15;423(6937):337-42. doi: 10.1038/nature01658. PMID: 12748652.
* Mundy GR. Osteoporosis and inflammation. Nutr Rev. 2007 Dec;65(12 Pt 2):S147-51. doi: 10.1111/j.1753-4887.2007.tb00353.x. PMID: 18240539.
* Pageau SC. Denosumab. MAbs. 2009 May-Jun;1(3):210-5. doi: 10.4161/mabs.1.3.8592. Epub 2009 May 29. PMID: 20065634; PMCID: PMC2726593.
* Lacativa PG, Farias ML. Osteoporosis and inflammation. Arq Bras Endocrinol Metabol. 2010 Mar;54(2):123-32. doi: 10.1590/s0004-27302010000200007. PMID: 20485900.
* Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011 Apr 9;377(9773):1276-87. doi: 10.1016/S0140-6736(10)62349-5. Epub 2011 Mar 28. PMID: 21450337; PMCID: PMC3555696.
* Kenkre JS, Bassett J. The bone remodelling cycle. Ann Clin Biochem. 2018 May;55(3):308-327. doi: 10.1177/0004563218759371. Epub 2018 Mar 4. PMID: 29368538.
* Cheng CH, Chen LR, Chen KH. Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover. Int J Mol Sci. 2022 Jan 25;23(3). doi: 10.3390/ijms23031376. Epub 2022 Jan 25. PMID: 35163300; PMCID: PMC8836058.
* Yu B, Wang CY. Osteoporosis and periodontal diseases - An update on their association and mechanistic links. Periodontol 2000. 2022 Jun;89(1):99-113. doi: 10.1111/prd.12422. Epub 2022 Mar 4. PMID: 35244945; PMCID: PMC9067601.
* Peng R, Dong Y, Zheng M, Kang H, Wang P, Zhu M, Song K, Wu W, Li F. IL-17 promotes osteoclast-induced bone loss by regulating glutamine-dependent energy metabolism. Cell Death Dis. 2024 Feb 5;15(2):111. doi: 10.1038/s41419-024-06475-2. Epub 2024 Feb 5. PMID: 38316760; PMCID: PMC10844210.
* Hennen EM, Uppuganti S, de la Visitación N, Chen W, Krishnan J, Vecchi LA 3rd, Patrick DM, Siedlinski M, Lemoli M, Delgado R, de Caestecker MP, Chang W, Guzik TJ, Johnson RW, Harrison DG, Nyman JS. Hypertension promotes bone loss and fragility by favoring bone resorption in mouse models. J Clin Invest. 2025 Oct 15;135(20). doi: 10.1172/JCI184325. Epub 2025 Aug 19. PMID: 40828611; PMCID: PMC12547992.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.